CD33-TIM3 split CAR T cells

CD33-TIM3 split CAR T cells are an experimental, preclinical-stage cellular immunotherapy being investigated for the treatment of acute myeloid leukemia (AML). This dual-targeting chimeric antigen receptor (CAR) T-cell therapy simultaneously targets CD33, a myeloid-associated antigen, and TIM3 (T-cell immunoglobulin and mucin-domain containing-3), which is expressed on leukemic stem cells but not on healthy hematopoietic stem cells. The 'split' CAR architecture utilizes an 'AND' gating strategy, where the primary activation signal (CD3z) and the costimulatory signal (e.g., CD28 or 4-1BB) are separated into two distinct CAR constructs. Full T-cell activation and cytotoxicity occur only when both antigens are encountered on the same target cell, a design intended to enhance tumor specificity and mitigate on-target, off-tumor toxicity against healthy hematopoietic progenitor cells.

Other names

CD33-TIM3 dual CAR T cellsCD-33-TIM3 dual CAR T cellsCD 33-TIM3 dual CAR T cells